The conversion question, "20 units is how many mg," almost always applies to people using compounded semaglutide from multi-dose vials with insulin syringes
Taylor JR, Robbins TW (1986)
( Drugs.com
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
What follows is an honest map of where the mechanism is solid, where the evidence stops, and what better-evidenced options are sitting in the same slot
Small molecule GLP-RAs hold a potential to transform the landscape of metabolic and chronic disease management